共 5 条
[1]
Antiobesity efficacy of GLP‐1 receptor agonist liraglutide is associated with peripheral tissue‐specific modulation of lipid metabolic regulators[J] Juan Decara;Sergio Arrabal;Daniel Beiroa;Patricia Rivera;Antonio Vargas;Antonia Serrano;Francisco Javier Pavón;Joan Ballesteros;Carlos Dieguez;Rubén Nogueiras;Fernando Rodríguez de Fonseca;Juan Suárez BioFactors 2016,
[2]
Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model[J] Midhat H. Abdulreda;Rayner Rodriguez-Diaz;Alejandro Caicedo;Per-Olof Berggren Cell Metabolism 2016,
[3]
Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study[J] Weijian Ke;Liehua Liu;Juan Liu;Ailing Chen;Wanping Deng;Pengyuan Zhang;Xiaopei Cao;Zhihong Liao;Haipeng Xiao;Jianbin Liu;Yanbing Li;Liping Yu Journal of Diabetes Research 2015,
[4]
Short‐term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps[J] Jianping Weng;Ravi Retnakaran;Ammini Ariachery C;Linong Ji;Luigi Meneghini;Wenying Yang;Jeong‐Taek Woo Diabetes Metab Res Rev 2015,
[5]
The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus[J] R. E. Pratley;C. Weyer Diabetologia 2001,

